Data from the following clinical trials are discussed:

P1-18-16: First-line aromatase inhibitor + palbociclib with randomized switch to fulvestrant [Faslodex] + palbociclib upon detection of circulating 

 mutation in HR+/HER2 metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase 3 trial

PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2 advanced breast cancer across the MONALEESA studies

PD13-03: Ribociclib [Kisqali], everolimus, exemestane [Aromasin] triplet therapy in HR+/HER2 advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1

PD02-04: Molecular plasticity of luminal A breast cancer and response to CDK4/6 inhibition: The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Videos

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor degrader (SERD), combined with palbociclib [Ibrance] in postmenopausal women with ER+/HER2 advanced breast cancer

GS2 -02: Elacestrant, an oral selective estrogen receptor degrader (SERD) vs investigator's choice of endocrine monotherapy for ER+/HER2 advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC estrogen receptor degrader, in ER+/HER2 locally advanced or metastatic breast cancer

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Aditya Bardia, MD, MPH

Articles

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

SABCS 2021 Updates in ER+ Breast Cancer